STOCK GOODIES PLAYS OF THE WEEK

[bobky]

AMDA-IPO'ed today at 6.00 a share--some info-We are a commercial biomaterial company focused on using our silicon nitride
technology platform to develop, manufacture and sell a broad range of medical
devices. We currently market spinal fusion products and are developing products
for use in total hip and knee joint replacements. We believe

our silicon nitride
technology platform enables us to offer new and transformative products in the
orthopedic and other medical device markets. We believe we are the first and
only company to use silicon nitride in medical applications and over 14,000 of
our silicon nitride spine products have been implanted in patients.

Biomaterials are synthetic or natural materials available in a variety of forms
that are used in virtually every medical specialty. We believe our silicon
nitride biomaterial has superior characteristics compared to commonly used
biomaterials in the markets we are targeting, including polyetheretherketone, or
PEEK, which is the most common biomaterial used for interbody spinal fusion
products. Specifically, we believe our silicon nitride has the following key
attributes: promotion of bone growth; hardness, strength and resistance to
fracture; resistance to wear; non-corrosive; anti-infective properties; and
superior diagnostic imaging compatibility.

We currently market our Valeofamily of silicon nitride interbody spinal fusion
devices in the United States and Europe for use in the cervical and
thoracolumbar areas of the spine. We believe our Valeo devices have a number of
advantages over existing products due to silicon nitride's key characteristics,
resulting in faster and more effective fusion and reduced risk of infection. To
date, the rate of adverse events reported to the U.S. Food and Drug
Administration, or FDA, for our implanted Valeo interbody spinal fusion devices
is 0.1%.

In addition to our silicon nitride-based spinal fusion products, we market a
complementary line of non-silicon nitride spinal fusion products which allows us
to provide surgeons and hospitals with a broader range of products. These
products include three lines of spinal fusion devices and five types of
orthobiologics, which are used by surgeons to help promote bone growth and
fusion in spinal fusion procedures. Although our non-silicon nitride products
have accounted for approximately 70% or more of our product revenues for the
years ended December 31, 2012 and 2011 and the nine months ended September 30,
2013, we believe the continued promotion and potential for adoption of our
silicon nitride products and product candidates, if approved, provides us the
greatest opportunity to grow our business in new and existing markets and
achieve our goal to become a leading biomaterial company.

We are also incorporating our silicon nitride technology into components for use
in total hip and knee replacement product candidates that we are, or plan on,
developing in collaboration with a strategic partner. We believe that our
silicon nitride total hip and knee product candidates will provide competitive
advantages over current products made with traditional biomaterials. We believe
our silicon nitride technology platform can be used for developing products in
other markets and have developed prototypes for use in the dental, sports
medicine and trauma markets. As a result of some of the key characteristics of
our silicon nitride, we also believe our coating technology may be used to
enhance our metal products as well as commercially available metal spinal
fusion, joint replacement and other medical products.

We operate a 30,000 square foot manufacturing facility located at our corporate
headquarters in Salt Lake City, Utah, and we are the only vertically integrated
silicon nitride orthopedic medical device manufacturer in the world. We market
and sell our products to surgeons and hospitals in the United States and select
markets in Europe and South America through our established network of more than
50 independent sales distributors who are managed by our experienced in-house
sales and marketing management team.
---

We were incorporated in Delaware in 1996 under the name Amedica Corp. and have
since changed our name to Amedica Corporation. Effective September 20, 2010, we
acquired all of the outstanding shares of US Spine, Inc. which then became our
wholly-owned subsidiary, which is our only subsidiary. Our principal executive
offices are located at 1885 West 2100 South, Salt Lake City, Utah 84119, and our
telephone number is [phone]. Our web site address is www.amedicacorp.com.



Read more: http://www.nasdaq.com/markets/ipos/company/amedica-corp-603456-73919#ixzz2tDWFhWvr